Plavix is a registered trademark used to treat heart disease. The FDA issued a warning in 2010 recognizing the need for CYP2C19 testing when prescribing Plavix to help determine treatment for patients undergoing certain procedures. Carriers of certain CYP2C19 mutations have a higher risk of major cardiac events after a procedure and increased healthcare costs or death. A genetic test is available that can provide results in one hour and a comprehensive report on genetic factors that affect certain medications.

1. Plavix is a registered trademark of Sanofi-Aventis/Bristol-Myers Squibb. References: (1) Mega JL et al. (2009). N Engl J Med. 360: 354-62. (2) Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109-111. (3) dbSNP Short Genetic
Variations. Reference SNP (refSNP) Cluster Report: rs12248560. (4) American Heart Association (2006). Heart Disease and Stroke Statistics – 2006 Update. Dallas, TX. (5) Reese ES et al. (2012). Pharmacotherapy. 32(4): 323-332.
In 2010, the FDA issued a blackbox
warning for Plavix® (clopidogrel),
recognizing the need for CYP2C19
testing and tailored treatment for ACS
patients undergoing PCI.
Carriers of CYP2C19 loss-of-function
mutations have a higher risk of Major
Adverse Cardiac Events.¹ This can lead
to increased healthcare costs and
potentially death.
*2/*21 Hour
Sample sent to
GenoPATH
Follow-up with
patient
CYP2C19
Genotype
Spartan CYP2C19
Test
Cheek swab from
patient
2 Weeks Comprehensive
report
GenoPATH can provide CYP2C19 test results in 1 hour. A comprehensive
pharmacogenetic report from GenoPATH is also available.
www.GenoPATH.com1-855-GENOPATH
ACS and CYP2C19 Testing
1,200,000
heart attacks occur
annually in the US.⁴
$27,160
of people carry CYP2C19
mutations that can affect the
metabolism of clopidogrel.²³
can be saved per MACE
event avoided for every
30 patients genotyped.⁵
30%